drugset / Trial / NCT07165015

A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

NCT07165015

Phase 1 Completed 31 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the amount of LY3537031 that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants.

Timeline

Start
2025-09-18
Primary completion
2026-04-16
Completion
2026-04-16

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3537031 Unknown Subcutaneous